Depo-Provera Long-Term Use Risks

The Compounding Risks of Extended Use

Depo-Provera was designed as a short-term contraceptive option, yet millions of women used it for years or even decades. The FDA's 2004 black box warning recommended limiting use to 2 years due to bone density loss, but compliance was poor — many providers continued prescribing without alternative discussions. Each additional year of use compounds multiple risk pathways.

Meningioma Risk Escalation

The meningioma risk escalates dramatically with duration: 23% increased risk for ≤1 year, 150% for 1–3 years, and up to 460% for >3 years. Women who used Depo-Provera for 5, 10, or 15+ years accumulated massive cumulative MPA doses with correspondingly elevated brain tumor risk.

Bone Density Loss

Long-term MPA suppresses estrogen, causing significant bone mineral density loss — particularly in the spine and hips. While some bone density recovery occurs after discontinuation, it may not fully reverse. The bone density loss is especially concerning for women who began Depo-Provera use at young ages before achieving peak bone mass.

Other Long-Term Effects

Weight gain (average 5+ pounds per year of use), depression and mood changes, cardiovascular risk factors, delayed return to fertility (up to 18 months after discontinuation), and changes in menstrual patterns. These additional harms may be compensable in a lawsuit alongside the primary meningioma claim.